Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMJBU9V)

Drug Name
Velimogene aliplasmid Drug Info
Synonyms Allovectin (TN)
Indication
Disease Entry ICD 11 Status REF
Melanoma 2C30 Phase 3 [1]
Cross-matching ID
TTD Drug ID
DMJBU9V

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
HLA class I antigen B-7 (HLA-B) TTGS10J 1B07_HUMAN Modulator [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
HLA class I antigen B-7 (HLA-B) DTT HLA-B 11.1 11.819 10.786 11.391
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

ICD Disease Classification 02 Neoplasm
Disease Class ICD-11: 2C82 Prostate cancer
The Studied Tissue Skin
The Studied Disease Melanoma [ICD-11:2C82]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
HLA class I antigen B-7 (HLA-B) DTT HLA-B 1.12E-04 1.11 1.21
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT00050388) Phase II Trial of Allovectin-7 for Head and Neck Cancer. U.S. National Institutes of Health.
2 Velimogene aliplasmid. Expert Opin Biol Ther. 2010 May;10(5):841-51.